These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15896322)

  • 1. Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells.
    Machida Y; Chiba T; Takayanagi A; Tanaka Y; Asanuma M; Ogawa N; Koyama A; Iwatsubo T; Ito S; Jansen PH; Shimizu N; Tanaka K; Mizuno Y; Hattori N
    Biochem Biophys Res Commun; 2005 Jun; 332(1):233-40. PubMed ID: 15896322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation].
    Hattori N; Machida Y; Noda K
    Rinsho Shinkeigaku; 2005 Nov; 45(11):905-7. PubMed ID: 16447759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
    Jiang H; Ren Y; Zhao J; Feng J
    Hum Mol Genet; 2004 Aug; 13(16):1745-54. PubMed ID: 15198987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
    Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
    Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
    Baptista MJ; Cookson MR; Miller DW
    Neuroscientist; 2004 Feb; 10(1):63-72. PubMed ID: 14987449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
    Yang Y; Nishimura I; Imai Y; Takahashi R; Lu B
    Neuron; 2003 Mar; 37(6):911-24. PubMed ID: 12670421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
    Haywood AF; Staveley BE
    BMC Neurosci; 2004 Apr; 5():14. PubMed ID: 15090075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
    Moussa CE; Wersinger C; Tomita Y; Sidhu A
    Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
    Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
    J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
    Chung KK; Zhang Y; Lim KL; Tanaka Y; Huang H; Gao J; Ross CA; Dawson VL; Dawson TM
    Nat Med; 2001 Oct; 7(10):1144-50. PubMed ID: 11590439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
    Corti O; Brice A
    Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cast of molecular characters in Parkinson's disease: felons, conspirators, and suspects.
    Lim KL; Dawson VL; Dawson TM
    Ann N Y Acad Sci; 2003 Jun; 991():80-92. PubMed ID: 12846976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways of neurodegeneration in Parkinson's disease.
    Dawson TM; Dawson VL
    Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkin and defective ubiquitination in Parkinson's disease.
    Dawson TM
    J Neural Transm Suppl; 2006; (70):209-13. PubMed ID: 17017531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into Parkinson's disease.
    Chung KK; Dawson VL; Dawson TM
    J Neurol; 2003 Oct; 250 Suppl 3():III15-24. PubMed ID: 14579120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in research on Parkinson disease: synuclein and parkin.
    Burke RE
    Neurologist; 2004 Mar; 10(2):75-81. PubMed ID: 14998437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.